Introduction:
Piramal Pharma Solutions plans for the expansion of manugacturing facility in Scotland and upgradation of current Active Pharmaceutical Ingredient (API) manufacturing in Morpeth, England.
Features:
The construction of new state-of-the-art Antibody-Drug Conjugate (ADC)is due to various pipeline products moving to commercial scale, combined with increasedcustomer demand for ADCs and APIs.
Expansion of Grangemouth Site
The new facility covers an area of 5-acre brownfieldplot less than 100 meters from the current site to meet the highest standards of globalcompliance.
First phase of the expansion features addition of two new ADC manufacturing suitesadded to the existing site. Moreover, the expansion features new sterile fill/finish suite dedicated to ADCs and two additional largescale manufacturing suites capable of handling increased batch sizes.
A new customer experience center is also planned for clientsduring development and/or manufacturing activities.
The expansion is expected to be operational by Q3, and thereby create 40-50 new jobsaccounting to a total of more than 250 employees.
Morpeth Site API Investment
Morpeth site invests £10 millionfor the development of new equipment, infrastructure, and utility systems. In addition, this investment will meet the growing API customers needs by improving its footprint by replacing obsolete equipment with new, energyefficient alternatives.
Specifications:
| Name | Piramal Pharma Solutions |
| Type | Expansion |
| Budget | US$59.05 million |
| Year | 2023 |
